Conference Description:

The 2nd Cell Therapy Analytical Development Summit Europe is an unmissable event for Europe's top biotech and pharma! As the cell therapy industry continues to rapidly grow and evolve, the opportunity to learn from and collaborate with leading experts in the field will ensure that potency, characterisation and multi-region access are no longer bottlenecks in the cell therapy drug development pipeline.

With FDA regulatory holds on release assays and potency forming a prevailing bottleneck in the cell therapy space, there has never been a more important time for the European cell therapy community to unite to implement gold standard analytical development, effectively communicate with the EMA and secure market approval.

Join 100+ analytical development, CMC and process development industry experts to advance multi-region access, achieve consistent and scalable assay development and drive analytical standards to bring safe, high-quality cell therapies to patients across the European territories.

Attend the only cell therapy-focused, industry-facing and European-specific summit to gain valuable insights on everything analytical development: from comparability testing to batch-to-batch variability, potency assays to regulatory considerations...and more! Gain control of your manufacturing processes, assay development and analytical strategy with key thought leaders from the likes of Takeda, Novo Nordisk, Cellectis and Gadeta.

Join us at the 2nd Cell Therapy Analytical Development Summit Europe to gain a competitive edge in this fast-paced industry.

URL:
Tickets: https://go.evvnt.com/1702984-2?pid=154
Prices:
Drug Developer Pricing - Conference + Workshop Day: EUR 4496.00,
Drug Developer Pricing - Conference Only: EUR 2999.00,
Academic Pricing - Conference + Workshop Day: EUR 3946.00,
Academic Pricing - Conference Only: EUR 2599.00,
Service Provider Pricing - Conference + Workshop Day: EUR 5396.00,
Service Provider Pricing - Conference Only: EUR 3599.00

Speakers: Sharon Longhurst, Vice President, Development, Gadeta, Terri Gaskell, Chief Technology Officer, Rinri Therapeutics, Guillaume Cornelis, Associate Director and Principal Scientist, Analytical Development, Cellectis, Mahwish Natalia, Associate Director, Takeda Oncology, Sagi Nahum, Global Senior Director, Analytical Sciences, Chemistry, Manufacturing and Controls, Cell and Gene Therapy, Orgenesis, Sofia Hakansson Buch. Vice President, Cell Therapy Chemistry, Manufacturing and Controls, Novo Nordisk, Therese Choquette, Head of Analytical Sciences, Tigen Pharma, Rozanna Yaing, Managing Director, The Ankor, Ilya Shestopalov, Vice President, Analytical Development and Product Lead, bluebird bio, James Piret, Assistant Professor, University of British Columbia, Ben Espen, Principal Quality Engineer, Avobis Bio, Julien Browne, Associate Director and Head of Analytical Development, Quell Therapeutics, Srividya Sundararaman, Director, Analytical Development, Poseida Therapeutics, Chaminda Salgado, Vice President , Chemistry, Manufacturing and Controls, T-Cypher Bio, Ivan Horak, Chief Medical Officer and Chief Scientific Officer, Tessa Therapeutics, Owen Davies, Associate Professor, Molecular and Regenerative Biomedicine, Loughborough University, Anne-Sophie Petit, Senior Engineer, Analytical Development, Cellectis, Maria Castella, Production Manager, Immunotherapy, Hospital Clinic Barcelona, Jorge Burns, Assistant Professor, University of Ferrara, Benedetta di Robilant, Co-founder and Chief Scientific Officer, Dorian Therapeutics, Carmen Sanges, Scientific and Strategic Project Manager, University of Wurzburg

Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Drug Development

Date and Time: 19th September 2023 at 9:00 am to 21st September 2023 at 5:00 pm